ArticleBMC pulmonary medicine2026
Isoniazid-induced alopecia in isoniazid-monoresistant pulmonary tuberculosis.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlopecia is a rare adverse reaction during tuberculosis (TB) treatment. Both drug-resistant TB and isoniazid (INH)-induced alopecia have been reported. We present this case because INH monoresistance coexisting with INH-induced alopecia has not previously been described in the literature. CASE: A 22-year-old woman was diagnosed with pulmonary TB and initiated on antituberculosis treatment (ATT). After 1 month, she developed sudden, severe hair loss. INH was suspected as the causative agent and discontinued. Hair regrowth was observed within 1 month. Drug resistance testing revealed INH monoresistance. Treatment was continued with rifampicin (R), pyrazinamide, ethambutol (E), and moxifloxacin for 2 months, followed by R and E for 7 months.
conclusionClinicians should be vigilant for alopecia in young female patients receiving ATT, as it may lead to treatment interruption for cosmetic reasons. Alopecia may also signal underlying drug resistance, and further studies are needed to establish biological evidence for this association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.